Vitamin k for prevention and treatment of skin rash secondary to Anti-egfr therapy

Abstract

The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 671,563, filed Apr. 15, 2005, the content of which is hereby incorporated by reference in its entirety into the subject application.STATEMENT OF GOVERNMENT SUPPORT[0002]The invention disclosed herein was made with U.S. Government support under National Institutes of Health grant numbers CA 84119 and 91784. Accordingly, the U.S. Government has certain rights in this invention.BACKGROUND OF THE INVENTION[0003]Throughout this application various publications are referred to in parenthesis. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference in their entireties into the subject application to more fully describe the art to which the subject application pertains.[0004]The epidermal growth factor receptor (EGFR) is a transmembrane prote...

AI Technical Summary

Benefits of technology

[0010]The present invention provides a method for treating a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a vitamin K analog to the skin rash in an amount effective to treat the skin rash. The invention also provides a method for preventing a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a vitamin K analog to the skin in an amount effective to prevent the skin rash.

[0013]The present invention is also directed to a method for treating a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a phosphatase inhibitor to the skin rash in an amount effective to treat the skin rash. The invention further provides a method for preventing a skin rash, secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a phosphatase inhibitor to the skin in an amount effective to prevent the skin rash.

Problems solved by technology

Although these agents do not cause life threatening toxicities, the major side effect is a skin rash that occurs in 60-70% of patients, affects mostly face and trunk, and causes discomfort and unfavorable cosmetic changes in many cases.

There are no rational, scientifically proven and clinically effective methods available for the treatment of this form of skin rash.

Topical or systemic antibiotics, anti-inflammatory agents, retinoids, topical lubricants, and other types of remedies have been tried in an empirical fashion with poor or inconsistent results.

As of today there is no established therapy or prevention for this new skin disease, a condition that is expected to affect about 150,000 individuals in the USA every year in the very near future.

However, topical administration of vitamin K3 can cause dermatitis (Page et al, 1942) and vesiculation of the skin (Ulbrich, 1961).

Images